A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)

Category Primary study
ConferenceInternational journal of radiation oncology biology physics
Year 2022
This article has no abstract
Epistemonikos ID: 3ced7734081c360e9544aa5cb4f2f936fd67db3e
First added on: Feb 13, 2025